IL-17 inhibitors for psoriasis
The role of the Th17/interleukin (IL)-23 pathway has been well elucidated in psoriasis. The IL-17 family includes 6 cytokines: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F. Two monoclonal antibodies targeting IL-17A (secukinumab,ixekizumab) and one antibody against the IL-17 receptor (brodalumab) have been approved for the treatmentof moderate-to-severe plaque psoriasis. Clinical efficacy, safety, and tolerability of each agent is reviewed.